CTRI/2009/091/000547已完成4 期
A 6-weeks, double blind, active controlled, prospective, parallel, multicenter study to compare the efficacy and safety of a combination inhaler of Ciclesonide/Formoterol and Ciclesonide alone in subjects with persistent asthma
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Cipla Ltd
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Written informed consent.
- •2.Male or female between 18 and 70 years of age inclusive of both.
- •3.Confirmed diagnosis of asthma according to GINA guidelines
- •4.Subjects with documented history of asthma who are either steroid naïve, on ICS+LABA combination or are on ICS (maximum daily dose up to 800 mcg budesonide, 1000 mcg Beclomethasone dipropionate (BDP) or 500 mcg Fluticasone) for at least 4 weeks prior to run-in.
- •5.FEV1 greater than or equal to 40 percent and Lesser than 80 prcent of the predicted normal value (as per the European Community for Coal and Steel formula and applying the correction factor of 0.9) when not taking short-acting bronchodilator medication for the previous 6 hours.
- •6.Able to demonstrate a 12 percent and 200 ml improvement in FEV1 within 30 minutes after inhalation of salbutamol 200 mcg / levosalbutamol 100 mcg unless reversibility is documented in the previous 6 months
- •7.Able to use the peak flow meter and perform the required pulmonary function tests before entering the run-in period
- •8.In the opinion of the investigator, able to comply with the requirements of the protocol.
- •9.The subject should demonstrate correct use of the pMDI.
排除标准
- •1.Known or suspected hypersensitivity to ciclesonide, formoterol or any other constituents of the Investigational Medicinal Product (IMP).
- •2.Clinical evidence or known history of any serious uncontrolled medical condition [e.g., cardiovascular (high pulse rate, irregular heart beat, high blood pressure), renal, neurological, hepatic, immunological, neoplastic, gastrointestinal, or endocrine disease] or any clinically significant abnormality (e.g., pneumonia, pulmonary fibrotic disease, active tuberculosis, chronic obstructive pulmonary disease (COPD) or pneumothorax), which, in the opinion of the investigator, might compromise the safety of the subject or which might interfere with the study.
- •3.Clinically relevant respiratory tract infection, as judged by investigator in the 4 weeks preceding the run-in period.
- •4.Females who are pregnant, lactating or planning to become pregnant
- •5.Women of child bearing age who are unwilling to take adequate contraceptive precautions unless abstinence is considered adequate in the investigators opinion
- •6.Clinically significant laboratory values, as judged by the investigator.
- •7.Subjects who have previously been enrolled into this study.
- •8.Receipt of an investigational drug within 30 days prior to study entry (screening visit)
- •9.Subjects who are scheduled to receive any other investigational drug during the course of the study.
- •10.Hospitalisation due to exacerbation of asthma within the previous 12 weeks preceding study entry (screening visit)
- •11.Use of oral, depot or parenteral steroids within 4 weeks of the run-in period
- •12.A smoking history of > or = 10 pack years
研究者
相似试验
进行中（未招募）
不适用
The study is measuring the safety and effect of the study drug zicronapine in the treatment of patients with schizophrenia. Patients will receive either the study drug (zicronapine) or risperidone based on a computer-aided random draw, and no one involved in the study will know what treatment is given until the study has finished.MedDRA version: 14.0Level: PTClassification code 10039638Term: Schizophrenia, disorganised typeSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.0Level: PTClassification code 10039639Term: Schizophrenia, paranoid typeSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.0Level: PTClassification code 10052792Term: Schizophrenia, undifferentiated typeSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.0Level: PTClassification code 10039637Term: Schizophrenia, catatonic typeSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2010-022181-28-PLH. Lundbeck A/S160
进行中（未招募）
不适用
A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophreniaSchizophreniaEUCTR2010-022181-28-CZH. Lundbeck A/S160
进行中（未招募）
不适用
The study is measuring the safety and effect of the study drug zicronapine in the treatment of patients with schizophrenia. Patients will receive either the study drug (zicronapine) or risperidone based on a computer-aided random draw, and no one involved in the study will know what treatment is given until the study has finished.SchizophreniaEUCTR2010-022181-28-FIH. Lundbeck A/S160
进行中（未招募）
不适用
The study is measuring the safety and effect of the study drug zicronapine in the treatment of patients with schizophrenia. Patients will receive either the study drug (zicronapine) or risperidone based on a computer-aided random draw, and no one involved in the study will know what treatment is given until the study has finished.SchizophreniaEUCTR2010-022181-28-EEH. Lundbeck A/S160
进行中（未招募）
不适用
A 6-month, double-blind, double-dummy, randomised, parallel group, multicenter, efficacy and safety study of Symbicort® pMDI 2x160/4.5µg and 2x80/4.5µg bid compared to Formoterol Turbuhaler, Budesonide pMDI (& the combination) and Placebo in chronic obstructive pulmonary disease patients (COPD). - SHINEThis is an application for a phase III study to be conducted in COPD patients.Classification code 10010952EUCTR2004-001183-41-CZAstraZeneca AB1,500